Laura V Klotz1,2,3, Michael Lindner1,3, Martin E Eichhorn2, Uwe Grützner1, Ina Koch1, Hauke Winter2, Teresa Kauke1, Thomas Duell4, Rudolf A Hatz1,3. 1. Center for Thoracic Surgery Munich, Ludwig-Maximilians-University of Munich/Asklepios Lung Clinic Gauting, Gauting, Germany. 2. Department of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany. 3. Comprehensive Pneumology Center, Helmholtz Zentrum Munich, Munich, Germany. 4. Department of Pneumology, Asklepios Lung Clinic Gauting, Gauting, Germany.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective group of patients. We analyzed the influence of HITHOC following pleurectomy and decortication on postoperative morbidity and overall survival for patients suffering from localized mesothelioma. METHODS: From 2009 until 2013, 71 patients with localized pleural mesothelioma underwent pleurectomy and decortication followed by HITHOC with cisplatin and doxorubicin. We analyzed postoperative morbidity, age, overall survival and influence of macroscopic resection on survival. RESULTS: Median patient age was 70 years (range, 65-73 years). Patients having the sarcomatoid subtype of mesothelioma showed a poor median survival of 9.2 months. In contrast, patients having the epithelioid subtype had a median survival of 17.9 months. Patients following macroscopic complete resection had a significantly better survival with 28.2 months compared to 13.1 months in patients with incomplete resection of the mesothelioma (P<0.0001). HITHOC was performed in all patients after tumor resection using cisplatin and doxorubicin. CONCLUSIONS: Taken together, HITHOC following pleurectomy and decortication is supposed to be a safe therapeutic option for selected patients with localized epithelial pleural mesothelioma.
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective group of patients. We analyzed the influence of HITHOC following pleurectomy and decortication on postoperative morbidity and overall survival for patients suffering from localized mesothelioma. METHODS: From 2009 until 2013, 71 patients with localized pleural mesothelioma underwent pleurectomy and decortication followed by HITHOC with cisplatin and doxorubicin. We analyzed postoperative morbidity, age, overall survival and influence of macroscopic resection on survival. RESULTS: Median patient age was 70 years (range, 65-73 years). Patients having the sarcomatoid subtype of mesothelioma showed a poor median survival of 9.2 months. In contrast, patients having the epithelioid subtype had a median survival of 17.9 months. Patients following macroscopic complete resection had a significantly better survival with 28.2 months compared to 13.1 months in patients with incomplete resection of the mesothelioma (P<0.0001). HITHOC was performed in all patients after tumor resection using cisplatin and doxorubicin. CONCLUSIONS: Taken together, HITHOC following pleurectomy and decortication is supposed to be a safe therapeutic option for selected patients with localized epithelial pleural mesothelioma.
Authors: William G Richards; Lambros Zellos; Raphael Bueno; Michael T Jaklitsch; Pasi A Jänne; Lucian R Chirieac; Beow Y Yeap; Rene J Dekkers; Phillip M Hartigan; Leah Capalbo; David J Sugarbaker Journal: J Clin Oncol Date: 2006-04-01 Impact factor: 44.544
Authors: Raphael Bueno; Jason Reblando; Jonathan Glickman; Michael T Jaklitsch; Jeanne M Lukanich; David J Sugarbaker Journal: Ann Thorac Surg Date: 2004-11 Impact factor: 4.330
Authors: Eelco de Bree; Serge van Ruth; Paul Baas; Emiel J Th Rutgers; Nico van Zandwijk; Arjen J Witkamp; Frans A N Zoetmulder Journal: Chest Date: 2002-02 Impact factor: 9.410
Authors: John Stathopoulos; Dimosthenis Antoniou; George P Stathopoulos; Sotiris K Rigatos; John Dimitroulis; John Koutandos; Pinelopi Michalopoulou; Athanasios Athanasiades; Marinos Veslemes Journal: Anticancer Res Date: 2005 Sep-Oct Impact factor: 2.480
Authors: Eelco de Bree; Serge van Ruth; Carl E Schotborgh; Paul Baas; Frans A N Zoetmulder Journal: Ann Surg Oncol Date: 2007-07-20 Impact factor: 5.344
Authors: Antonia Marazioti; Anthi C Krontira; Sabine J Behrend; Georgia A Giotopoulou; Giannoula Ntaliarda; Anne-Sophie Lamort; Georgios T Stathopoulos; Christophe Blanquart; Hasan Bayram; Marianthi Iliopoulou; Malamati Vreka; Lilith Trassl; Mario A A Pepe; Caroline M Hackl; Laura V Klotz; Stefanie A I Weiss; Ina Koch; Michael Lindner; Rudolph A Hatz; Juergen Behr; Darcy E Wagner; Helen Papadaki; Sophia G Antimisiaris; Didier Jean; Sophie Deshayes; Marc Grégoire; Özgecan Kayalar; Deniz Mortazavi; Şükrü Dilege; Serhan Tanju; Suat Erus; Ömer Yavuz; Pınar Bulutay; Pınar Fırat; Ioannis Psallidas; Magda Spella; Ioanna Giopanou; Ioannis Lilis Journal: EMBO Mol Med Date: 2021-12-13 Impact factor: 12.137
Authors: Ioannis Karampinis; Anna Dionysopoulou; Christian Galata; Katrin Almstedt; Maurizio Grilli; Annette Hasenburg; Eric D Roessner Journal: Thorac Cancer Date: 2022-02-22 Impact factor: 3.500